Patent Assignment
Reel/Frame 036307/0406
Release of Security Interest
Recorded: 2015-08-07
Pages: 49
Assignee
CYMABAY THERAPEUTICS, INC.
7999 GATEWAY BOULEVARD, SUITE 130, NEWARK, CALIFORNIA, 94560
Covered Properties
(68)
Bioadhesive Compositions for Epithelial Drug Delivery
PCT:
PCT/US2011/038906 ↗
Compositions of 5-Ethyl-2-{4-[4-(4-Tetrazol-1-Yl-Phenoxymethyl)-Thiazol-2-Yl]-Piperidin-1-Yl}-Pyrimidine
PCT:
PCT/US2011/040972 ↗
Methods for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halofenic Acid and a Second Urate-Lowering Agent
PCT:
PCT/US2011/059394 ↗
Methods for Treating Gout in Patient Subpopulations
PCT:
PCT/US2011/059425 ↗
Methods for Treating Gout Flares
PCT:
PCT/US2011/059433 ↗
Agonists of GPR131 and Uses Thereof
PCT:
PCT/US2012/042319 ↗
Bicyclic Agonists of GPR131 and Uses Thereof
PCT:
PCT/US2012/052364 ↗
Dcc Mediated Coupling for Halofenate Manufacture
PCT:
PCT/US2013/022213 ↗
Method for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halofenic Acid and an Anti-Inflammatory Agent
PCT:
PCT/US2013/036474 ↗
Method of Solution Overcoating with Gelling Polymer
Patent:
5,738,876 →
Application:
08/713,138 →
Use of (-) (3-Trihalomethylphenoxy) (4-Halophenyl) Acetic Acid Derivatives for Treatment of Insulin Resistance, Type 2 Diabetes and Hyperlipidemia
Patent:
6,262,118 →
Application:
09/325,997 →
Use of (-) (3-Trihalomethylphenoxy) (4-Halophenyl) Acetic Acid Derivatives for Treatment of Insulin Resistance, Type 2 Diabetes, Hyperlipidemia and Hyperuricemia
Patent:
6,613,802 →
Application:
09/585,907 →
Use of (-) (3-Trihalomethylphenoxy) (4-Halophenyl) Acetic Acid Derivatives for Treatment of Insulin Resistance, Type 2 Diabetes and Hyperlipidemia
Patent:
6,646,004 →
Application:
09/703,487 →
Use of (-) (3-Trihalomethylphenoxy) (4-Halophenyl) Acetic Acid Derivatives for Treatment of Insulin Resistance, Type 2 Diabetes, Hyperlipidemia and Hyperuricemia
Patent:
6,624,194 →
Application:
09/724,788 →
Methods and Reagents for Diagnosis and Treatment of Diabetes
Compositions and Methods for Diagnosing and Treating Diabetes, Insulin Resistance and Dyslipidemia
Use of (-) (3-Trihalomethylphenoxy) (4-Halophenyl) Acetic Acid Derivatives for Treatment of Insulin Resistance, Type 2 Diabetes, Hyperlipidemia and Hyperuricemia
Substituted Phenylacetic Acids
An Isolated Islet Beta-Cell Two-Pore Domain Potassium Channel
Pancreatic Islet Transcription Factor and Uses Thereof
Resolution of Alpha-(Phenoxy)Phenylacetic Acid Derivatives
Methods and Compositions for Treating and Diagnosing Diabetes and Related Diseases Involving Beta-Trp
Compositions and Methods of Using Apoptosis Signaling Kinase Related Kinase (Askrk)
Alpha(Trifluoromethyl-Substituted Aryloxy, Arylamino, Arylthio or Arylmethyl)-Trifluoromethyl-Substituted Phenylacetic Acids and Derivatives as Antidiabetic Agents
Substituted Triazoles as Modulators of Ppar and Methods of Their Preparation
Modulators of Ppar and Methods of Their Preparation
Substituted Phenylacetic Acids
Polynucleotides Encoding an Isolated Beta-Islet Cell Two-Pore Domain Potassium Channel
CD39L3 and Its Role in Diabetes
Crystalline Solid and Amorphous Forms of (-)- Halofenate and Methods Related Thereto
Compositions and Methods of Using Apoptosis Signaling Kinase Related Kinase (Askrk)
Resolution of Alpha-(Phenoxy) Phenylacetic Acid Derivatives with Naphthyl-Alkylamines
Methods and Reagents for Diagnosis and Treatment of Diabetes
Compositions and Methods of Using Apoptosis Signaling Kinase Related Kinase (Askrk)
Patent:
40,624 →
Application:
11/900,008 →
Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer
5-Ethyl-2-{4-[4-(4-Tetrazol-1-Yl-Phenoxymethyl)-Thiazol-2-Yl]-Piperidin-1-Yl}-Pyrimidine
N-Linked Heterocyclic Receptor Agonists for the Treatment of Diabetes and Metabolic Disorders
Oxymethylene Aryl Compounds and Uses Thereof
Application:
12/414,639 →
Publication:
US 2009/0270404
Process for the Preparation of (-)-(4-Chloro-Phenyl)-(3-Trifluoromethyl-Phenoxy)-Acetic Acid 2-Acetylamino-Ethyl Ester
Use of (-) (3-Trihalomethylphenoxy) (4-Halophenyl) Acetic Acid Derivatives for Treatment of Hyperuricemia
Use of (-)(3-Trihalomethylphenoxy)(4-Halophenyl) Acetic Acid Derivatives for Treatment of Type 2 Diabetes
2,4-Disubsituted Thiazoles and Pharmaceutical Compositions Thereof
Methods of Reducing Small, Dense Ldl Particles
Application:
12/579,996 →
Publication:
US 2010/0152295
Aryl GPR120 Receptor Agonists and Uses Thereof
Application:
12/582,610 →
Publication:
US 2010/0216827
Heterocyclic Receptor Agonists for the Treatment of Diabetes and Metabolic Disorders
GPR120 Receptor Agonists and Uses Thereof
GPR120 Receptor Agonists and Uses Thereof
Substituted Tetrazol-1-Yl-Phenoxymethyl-Thiazol-2-Yl-Piperidinyl-Pyrimidine Salts
Compositions of 5-Ethyl-2-{4-[4-(4-Tetrazol-1-Yl-Phenoxymethyl)-Thiazol-2-Yl]-Piperidin-1-Yl}-Pyrimidine
Process for the Preparation of (-)-(4-Chloro-Phenyl)-(3-Trifluoromethyl-Phenoxy)-Acetic Acid 2-Acetylamino-Ethyl Ester
Application:
13/422,838 →
Publication:
US 2012/0232302
Use of (-) (3-Trihalomethylphenoxy) (4-Halophenyl) Acetic Acid Derivatives for Treatment of Insulin Resistance, Type 2 Diabetes, Hyperlipidemia and Hyperuricemia
N-Linked Heterocyclic Receptor Agonists for the Treatment of Diabetes and Metabolic Disorders
Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto
Agonists of GPR131 and Uses Thereof
Bicyclic Agonists of GPR131 and Uses Thereof
Heterocyclic Receptor Agonists for the Treatment of Diabetes and Metabolic Disorders
GPR120 Receptor Agonists and Uses Thereof
GPR120 Receptor Agonists and Uses Thereof
Methods for Treating Gout Flares
Methods for Treating Gout in Patients Subpopulations
Application:
13/668,024 →
Publication:
US 2013/0302305
Methods for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halofenic Acid and a Second Urate-Lowering Agent
Heterocyclic Receptor Agonists for the Treatment of Diabetes and Metabolic Disorders
DCC Mediated Coupling for Halofenate Manufacture
Substituted Tetrazol-1-Yl-Phenoxymethyl-Thiazol-2-Yl-Piperidinyl-Pyrimidine Salts
Method for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halofenic Acid and an Anti-Inflammatory Agent
Application:
13/862,262 →
Publication:
US 2013/0274331
Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto
Methods for Treating Gout Flares
Application:
13/961,848 →
Publication:
US 2014/0128439
GPR120 Receptor Agonists and Uses Thereof
Application:
14/054,385 →
Publication:
US 2014/0121246
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Oct 12, 1999
From: LUSKEY, KENNETH L.; LUO, JIAN
To: METABOLEX, INC.
Reel/Frame 010303/0283 →
Assignment of Assignor's Interest
May 29, 2001
From: LUSKEY, KENNETH A.; LUO, JIAN; ZHAO, ZUCHUN
To: METABOLEX, INC.
Reel/Frame 011848/0630 →
Assignment of Assignor's Interest
Jun 4, 2001
From: METABOLEX, INC.
To: DIATEX, INC.
Reel/Frame 011858/0175 →
Assignment of Assignor's Interest
May 28, 2002
From: METABOLEX, INC.
To: DIATEX, INC.
Reel/Frame 012935/0059 →
Assignment of Assignor's Interest
May 28, 2002
From: METABOLEX, INC.
To: DIATEX, INC.
Reel/Frame 012935/0184 →
Assignment of Assignor's Interest
Jul 31, 2002
From: METABOLEX, INC.
To: DIATEX, INC.
Reel/Frame 013137/0615 →
Assignment of Assignor's Interest
May 5, 2003
From: WATERS, STEVE; MOODIE, SHONNA; LAVAN, BRIAN; GUSTAFASON, THOMAS A.
To: METABOLEX, INC.
Reel/Frame 013628/0763 →
Assignment of Assignor's Interest
Jul 2, 2003
From: JOHNSON, JEFFREY D.; BLUME, JOHN E.; PALMA, JOHN F.; ZHOU, YUN-PING
To: METABOLEX, INC.
Reel/Frame 013773/0924 →
Assignment of Assignor's Interest
Jul 15, 2003
From: LUSKEY, KENNETH L.; LUO, JIAN
To: METABOLEX, INC.
Reel/Frame 013805/0490 →
Assignment of Assignor's Interest
Jul 23, 2003
From: METABOLEX, INC.
To: DIATEX, INC.
Reel/Frame 013824/0006 →
Assignment of Assignor's Interest
Jul 28, 2003
From: ZHAO, ZUCHUN; CHEN, XIN; WANG, JIANCHAO; SUN, HONGBIN
To: METABOLEX, INC.
Reel/Frame 014328/0187 →
Assignment of Assignor's Interest
Jan 26, 2004
From: DAUGS, EDWARD D.
To: METABOLEX, INC.
Reel/Frame 014941/0504 →
Assignment of Assignor's Interest
Sep 3, 2004
From: JOHNSON, JEFFREY D.; ZHOU, YUN-PING
To: METABOLEX, INC.
Reel/Frame 015105/0047 →
Assignment of Assignor's Interest
Oct 15, 2004
From: LUSKEY M.D., KENNETH L.; LUO M.D., JIAN
To: METABOLEX, INC.
Reel/Frame 015246/0783 →
Assignment of Assignor's Interest
Oct 19, 2004
From: LUSKEY, KENNETH L.; LUO, JIAN
To: METABOLEX, INC.
Reel/Frame 015259/0335 →
Assignment of Assignor's Interest
Dec 23, 2004
From: JOHNSON, JEFFREY D.; SCHWEITZER, ANTHONY C.; PALMA, JOHN F.; BLUME, JOHN E.
To: METABOLEX, INC.
Reel/Frame 015485/0864 →
Assignment of Assignor's Interest
Jun 16, 2005
From: ZHAO, ZUCHUN; CHEN, XIN; WANG, JIANCHAO; SUN, HONGBIN
To: METABOLEX, INC.
Reel/Frame 016702/0620 →
Assignment of Assignor's Interest
Jun 27, 2005
From: JOHNSON, JEFFREY D.; ZHOU, YUN-PING; MARLEN, KIMBERLY
To: METABOLEX, INC.
Reel/Frame 016426/0393 →
Assignment of Assignor's Interest
Sep 27, 2005
From: ZHU, YAN; MA, JINGYUAN; CHENG, PENG; ZHAO, ZUCHUN
To: METABOLEX, INC.
Reel/Frame 016843/0362 →
License
Jun 17, 2009
From: METABOLEX, INC.
To: DIATEX, INC.
Reel/Frame 022835/0388 →
Corrective Assignment to Correct the Nature of Con
Jul 16, 2009
From: METABOLEX, INC.
To: DIATEX, INC.
Reel/Frame 022973/0618 →
Assignment of Assignor's Interest
Aug 22, 2011
From: ALUR, HEMANT H.; HARWICK, JAMES A. H.; MONDAL, PRAVAKAR; JOHNSTON, THOMAS P.
To: TRILOGIC PHARMA LLC
Reel/Frame 026783/0770 →
Change of Name
Oct 30, 2013
From: METABOLEX, INC.
To: CYMABAY THERAPEUTICS, INC.
Reel/Frame 031516/0801 →
Change of Name
Oct 30, 2013
From: METABOLEX, INC.
To: CYMABAY THERAPEUTICS, INC.
Reel/Frame 031516/0081 →
Change of Name
Oct 30, 2013
From: METABOLEX, INC.
To: CYMABAY THERAPEUTICS, INC.
Reel/Frame 031516/0124 →